AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 291 min read$DTIL

Germano Geno J purchased $16K of DTIL

Germano Geno J purchased 2,609 shares of PRECISION BIOSCIENCES INC (DTIL) at $6.28 on 2026-09-25.

Original reporting
SEC EDGAR · Germano Geno J
Published Sep 29, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 11:15 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$DTIL
Neutral
low confidence
Mentioned
$DTIL
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DTILNeutralLow
01

Why it matters

The director's modest purchase adds a small positive data point but is unlikely to affect price.

02

Market read

Minor insider buy; limited trading relevance.

03

What to watch

Potential upcoming clinical data could make the insider's stake more meaningful.

Relevance 4/10Novelty 4/10Timing: after-hours filing today

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$DTILNeutralLow confidence
Context

Director Germano Geno J bought 2,609 shares of Precision Biosciences at $6.28, increasing his stake to 47,492 shares.

Expected impact

slight upward pressure as market absorbs the buy signal

Evidence & confidence

The transaction size ($16K) is minor relative to market cap; director purchases are watched but this amount is not material.

Market effects

Sector

None significant for the biotech sector.

Regional

No regional impact.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

The purchase could be a routine portfolio rebalancing, not a bullish signal.

Key entities

  • Company
    Precision Biosciences Inc

    Biotech firm developing gene editing therapies.

  • Individual
    Germano Geno J

    Director of Precision Biosciences.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

DTIL insider trading history →

Related articles

AUG 20
$DTILMedAI 8/10

Precision BioSciences Posts Q2 Loss; PBGENE-HBV Delivers Clinical CccDNA Elimination Data

Precision BioSciences (DTIL) reported a Q2 2026 net loss of $32.7M, an increase from the prior year. The company presented clinical data for PBGENE-HBV, showing cccDNA elimination in hepatitis B patients. PBGENE-DMD, for Duchenne muscular dystrophy, is advancing with initial safety data expected by year-end. Cash reserves total $112.4M, supporting operations through 2028.

rttnews.com3 min
AUG 20
$DTILMedAI 8/10

iECURE, Inc.: iECURE to Present Clinical Data from Ongoing OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM Annual Symposium

iECURE, Inc. announced that data from its OTC-HOPE clinical trial of ECUR-506 for neonatal-onset OTC deficiency will be presented at the SSIEM Annual Symposium. The presentation will include safety and metabolic control data. iECURE is a clinical-stage genome editing company, and Precision BioSciences (DTIL) is involved through its ARCUS nuclease technology.

finanznachrichten.de2 min
AUG 6
$DTILMed

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

PRECISION BIOSCIENCES INC (DTIL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update - First clinical biopsy evidence of direct cccDNA elimination from ongoing Phase 1 ELIMINATE-B trial; PBGENE-HBV treatment led to a 1-log reduction in cccDNA with <1% rem

SEC EDGAR 8-K6 min
MAY 27
$DTILHighAI 9/10

Precision BioSciences Shows First Evidence Of CccDNA Elimination In Hepatitis B Patients; Stock Up

Precision BioSciences (DTIL) reported first clinical biopsy evidence from its ELIMINATE-B study that PBGENE-HBV can eliminate and inactivate hepatitis B cccDNA. The company said cccDNA transcripts fell 10-fold after two doses, with remaining cccDNA showing indels that disrupt viral polymerase. It also reported pgRNA as a biomarker and durable HBsAg declines up to a year; 38 doses in 16 patients showed no dose-limiting toxicities.

rttnews.com6 min